Clinical Program Expansion
Biventricular Heart Failure (Bridge to Transplant)
Key Facts
About SynCardia Systems
SynCardia Systems is a pioneer and the sole commercially approved provider of a temporary total artificial heart (TAH) system, a critical solution for the most severe form of heart failure. Its technology replaces both failing ventricles and valves, serving as a bridge to transplant for patients who are not candidates for left ventricular assist devices (LVADs). As a wholly owned subsidiary of Picard Medical, the company operates commercially in the U.S. and Canada, with over 2,100 implants globally, and continues to focus on expanding clinical adoption and patient mobility through its portable driver systems. The company addresses a significant unmet need within the advanced heart failure market.
View full company profileTherapeutic Areas
Other Biventricular Heart Failure (Bridge to Transplant) Drugs
| Drug | Company | Phase |
|---|---|---|
| Freedom Portable Driver Adoption | SynCardia Systems | Commercial |